Literature DB >> 11163111

Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells.

E O Im1, Y H Choi, K J Paik, H Suh, Y Jin, K W Kim, Y H Yoo, N D Kim.   

Abstract

We have compared the anti-proliferative effects of ursodeoxycholic acid (UDCA), chenodeoxycholic acid (CDCA) and their derivatives, HS-1183, HS-1199 and HS-1200, on MCF-7 (wild-type p53) and MDA-MB-231 (mutant p53) cells. While UDCA and CDCA exhibited no significant effect, their novel derivatives inhibited the proliferation of both cell lines in a concentration-dependent manner, concomitant with apoptotic nuclear changes and the increase of a sub-G1 population and DNA fragmentation. Furthermore, we also observed an increase in the ratio of pro-apoptotic protein Bax to anti-apoptotic protein Bcl-2 and cleavages of lamin B and poly(ADP-ribose) polymerase (PARP) in MCF-7 and MDA-MB-231 cells. Cell cycle related proteins, cyclin D1 and D3, as well as retinoblastoma protein (pRb) were down-regulated, while the level of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) was increased in both cancer cells after treatment with novel bile acids. These findings suggest that these cytotoxic effects of novel bile acid derivatives on human breast carcinoma cells were mediated via apoptosis through a p53-independent pathway.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163111     DOI: 10.1016/s0304-3835(00)00671-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

1.  Synthetic CDCA derivatives-induced apoptosis of stomach cancer cell line SNU-1 cells.

Authors:  Bongkyung Moon; Min-Chan Kim; Joo-sung Park
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

2.  Synthesis and evaluation of bile acid amides of [Formula: see text]-cyanostilbenes as anticancer agents.

Authors:  Devesh S Agarwal; Rajnish Prakash Singh; K Lohitesh; Prabhat N Jha; Rajdeep Chowdhury; Rajeev Sakhuja
Journal:  Mol Divers       Date:  2017-12-13       Impact factor: 2.943

3.  Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in mice.

Authors:  Hui Liu; Hong-Wei Xu; Yu-Zhen Zhang; Ya Huang; Guo-Qing Han; Tie-Jun Liang; Li-Li Wei; Cheng-Yong Qin; Cheng-Kun Qin
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 4.  Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents.

Authors:  M Mikov; J P Fawcett; K Kuhajda; S Kevresan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jul-Sep       Impact factor: 2.441

5.  Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines.

Authors:  Hui Liu; Cheng-Yong Qin; Guo-Qing Han; Hong-Wei Xu; Mei Meng; Zhen Yang
Journal:  World J Gastroenterol       Date:  2007-03-21       Impact factor: 5.742

6.  Effects of DCA on Cell Cycle Proteins in Colonocytes.

Authors:  Yun-Hyung Ha; Dong-Guk Park
Journal:  J Korean Soc Coloproctol       Date:  2010-08-31

Review 7.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

8.  The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway.

Authors:  Jean-Cheng Kuo; Won-Jing Wang; Chung-Chen Yao; Pei-Rung Wu; Ruey-Hwa Chen
Journal:  J Cell Biol       Date:  2006-02-13       Impact factor: 10.539

Review 9.  Plasma membrane transporters in modern liver pharmacology.

Authors:  Jose J G Marin
Journal:  Scientifica (Cairo)       Date:  2012-10-14

10.  U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways.

Authors:  Yang Xu; Qiang Luo; Ting Lin; Zhiping Zeng; Guanghui Wang; Dequan Zeng; Rong Ding; Cuiling Sun; Xiao-Kun Zhang; Haifeng Chen
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.